See more : Ganges Securities Limited (GANGESSEC.BO) Income Statement Analysis – Financial Results
Complete financial analysis of AbClon Inc. (174900.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AbClon Inc., a leading company in the industry within the sector.
- WinWay Technology Co., Ltd. (6515.TW) Income Statement Analysis – Financial Results
- Panjit International Inc. (2481.TW) Income Statement Analysis – Financial Results
- Morgan Stanley (0QYU.L) Income Statement Analysis – Financial Results
- Koramco Energy Plus Reit (357120.KS) Income Statement Analysis – Financial Results
- OneForce Holdings Limited (1933.HK) Income Statement Analysis – Financial Results
AbClon Inc. (174900.KQ)
Website: https://www.abclon.com
About AbClon Inc.
AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company's products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 3.08B | 3.41B | 3.02B | 2.77B | 14.38B |
| Cost of Revenue | 874.44M | 1.03B | 1.40B | 1.56B | 1.39B |
| Gross Profit | 2.21B | 2.38B | 1.62B | 1.21B | 12.98B |
| Gross Profit Ratio | 71.63% | 69.82% | 53.62% | 43.78% | 90.31% |
| Research & Development | 10.73B | 8.69B | 9.63B | 5.86B | 2.82B |
| General & Administrative | 251.40M | 89.25M | 274.74M | 213.43M | 5.19M |
| Selling & Marketing | 577.49M | 618.11M | 504.58M | 462.05M | 3.76B |
| SG&A | 828.89M | 707.35M | 779.32M | 675.47M | 5.07B |
| Other Expenses | 2.15B | 29.85M | 25.95M | -5.07M | 0.00 |
| Operating Expenses | 13.71B | 11.13B | 11.85B | 7.78B | 8.49B |
| Cost & Expenses | 14.59B | 12.16B | 13.25B | 9.34B | 9.88B |
| Interest Income | 860.23M | 258.84M | 148.30M | 328.00M | 206.78M |
| Interest Expense | 1.35B | 489.59M | 178.74M | 189.03M | 40.00 |
| Depreciation & Amortization | 1.68B | 1.52B | 1.39B | 1.13B | 500.80M |
| EBITDA | -9.72B | -8.34B | -8.83B | -5.44B | 4.78B |
| EBITDA Ratio | -315.30% | -203.06% | -287.09% | -185.02% | 33.28% |
| Operating Income | -11.51B | -8.75B | -10.23B | -6.57B | 4.28B |
| Operating Income Ratio | -373.24% | -256.86% | -338.93% | -237.13% | 29.80% |
| Total Other Income/Expenses | -1.25B | -1.60B | -8.62M | 126.43M | 420.48M |
| Income Before Tax | -12.75B | -10.35B | -10.24B | -6.44B | 4.70B |
| Income Before Tax Ratio | -413.74% | -303.81% | -339.22% | -232.57% | 32.72% |
| Income Tax Expense | 10.95M | -1.10B | 169.91M | 315.47M | 2.14B |
| Net Income | -12.77B | -9.25B | -10.24B | -6.44B | 2.57B |
| Net Income Ratio | -414.09% | -271.66% | -339.22% | -232.57% | 17.85% |
| EPS | -841.00 | -612.00 | -670.00 | -447.00 | 178.87 |
| EPS Diluted | -830.84 | -612.00 | -670.00 | -447.00 | 176.55 |
| Weighted Avg Shares Out | 15.18M | 15.12M | 15.28M | 14.42M | 14.35M |
| Weighted Avg Shares Out (Dil) | 15.36M | 15.12M | 15.28M | 14.42M | 14.54M |
Source: https://incomestatements.info
Category: Stock Reports